PMID- 38021786
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 10
DP  - 2023 Oct
TI  - An Exosome-Related Long Non-coding RNA (lncRNA)-Based Signature for Prognosis and 
      Therapeutic Interventions in Lung Adenocarcinoma.
PG  - e47574
LID - 10.7759/cureus.47574 [doi]
LID - e47574
AB  - Background The poor prognosis of lung adenocarcinoma (LUAD) has been confirmed by 
      a large number of studies, so it is necessary to construct a prognosis model. In 
      addition, exosome is closely related to tumors, but there are few studies on 
      exosome-related long non-coding RNA (lncRNA) (ExolncRNA). Methods In this study, 
      we designed a prognostic model, exosome-related lncRNA-based signature 
      (ExoLncSig), using ExolncRNA expression profiles of LUAD patients from The Cancer 
      Genome Atlas (TCGA). ExolncRNAs were identified through univariate and 
      multivariate and Lasso analyses. Subsequently, based on the ExoLncSig, gene 
      ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, immune 
      function and immunotherapy analysis, drug screening, and so on were performed. 
      Results AC026355.2, AC108136.1, AL590428.1, and LINC01312 were examined to 
      establish the ExoLncSig. Gene enrichment analysis identified potential prognostic 
      markers and therapeutic targets, including human leukocyte antigen (HLA), 
      parainflammation, chemokine receptor (CCR), antigen-presenting cell (APC) 
      co-inhibition, cancer-associated fibroblast (CAF), and myeloid-derived suppressor 
      cell (MDSC). Moreover, we ascertained that the high-risk subgroup exhibits 
      heightened susceptibility to pharmaceutical agents. Conclusion Our findings 
      indicate that ExoLncSig holds promise as a valuable prognostic marker in LUAD. 
      Furthermore, the immunogenic properties of ExolncRNAs may pave the way for the 
      development of a therapeutic vaccine against LUAD.
CI  - Copyright (c) 2023, Li et al.
FAU - Li, Jinghong
AU  - Li J
AD  - Computational Oncology Laboratory, Marine Biomedical Research Institute, 
      Guangdong Medical University, Zhanjiang, CHN.
FAU - Wang, Junhua
AU  - Wang J
AD  - Oncology Department, Qingdao Hospital, University of Health and Rehabilitation 
      Sciences (Qingdao Municipal Hospital), Qingdao, CHN.
FAU - Chen, Zhihong
AU  - Chen Z
AD  - Computational Oncology Laboratory, Marine Biomedical Research Institute, 
      Guangdong Medical University, Zhanjiang, CHN.
FAU - Hu, Pan
AU  - Hu P
AD  - Computational Oncology Laboratory, Marine Biomedical Research Institute, 
      Guangdong Medical University, Zhanjiang, CHN.
FAU - Zhang, Xiaodan
AU  - Zhang X
AD  - Computational Oncology Laboratory, Marine Biomedical Research Institute, 
      Guangdong Medical University, Zhanjiang, CHN.
FAU - Guo, Xiaojun
AU  - Guo X
AD  - Computational Oncology Laboratory, Marine Biomedical Research Institute, 
      Guangdong Medical University, Zhanjiang, CHN.
FAU - Zhu, Xiao
AU  - Zhu X
AD  - Genetics Department, Marine Biomedical Research Institute, Guangdong Medical 
      University, Zhanjiang, CHN.
FAU - Huang, Yongmei
AU  - Huang Y
AD  - Computational Oncology Laboratory, Marine Biomedical Research Institute, 
      Guangdong Medical University, Zhanjiang, CHN.
LA  - eng
PT  - Journal Article
DEP - 20231024
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10666655
OTO - NOTNLM
OT  - drug therapy
OT  - exosome-related lncrna
OT  - lung adenocarcinoma
OT  - prognostic model
OT  - tumor microenvironment
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/10/24
CRDT- 2023/11/29 15:12
PHST- 2023/10/24 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 15:12 [entrez]
PHST- 2023/10/24 00:00 [pmc-release]
AID - 10.7759/cureus.47574 [doi]
PST - epublish
SO  - Cureus. 2023 Oct 24;15(10):e47574. doi: 10.7759/cureus.47574. eCollection 2023 
      Oct.